Litigation Details for Janssen Biotech Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)

Janssen Biotech Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)

Docket		Date Filed	2015-08-03
Court	District Court, D. Delaware	Date Terminated	2015-10-28
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	8,822,438
Link to Docket	External link to docket

Details for Janssen Biotech Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-03				External link to document

Janssen Biotech Inc. v. Par Pharmaceutical Inc. | 1:15-cv-00679 Patent Litigation Summary

Last updated: August 4, 2026

Janssen Biotech Inc. v. Par Pharmaceutical Inc., Case No. 1:15-cv-00679, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Par's abbreviated new drug application for generic abiraterone acetate tablets, the active ingredient in Zytiga. Janssen asserted U.S. Patent No. 8,822,438, which covered methods of treating prostate cancer with abiraterone acetate.

The case was part of a broader group of Zytiga ANDA lawsuits filed by Janssen against generic manufacturers. The action did not produce a final merits judgment against Par. The dispute was resolved through a settlement and the case was terminated. Later litigation involving other generic applicants resulted in a Federal Circuit determination that the asserted '438 patent claims were invalid for obviousness, materially reducing the practical value of the patent estate.

What drug and patents were at issue in Janssen v. Par?

The litigation concerned abiraterone acetate tablets, marketed by Janssen as Zytiga.

Item	Detail
Brand drug	Zytiga
Active ingredient	Abiraterone acetate
Therapeutic class	Androgen biosynthesis inhibitor
Primary indication	Metastatic castration-resistant prostate cancer
NDA holder	Janssen Biotech Inc.
Generic pathway	ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00679
Presiding judge	Richard G. Andrews
Asserted patent	U.S. Patent No. 8,822,438
Patent subject matter	Methods of treating prostate cancer with abiraterone acetate
Litigation type	Paragraph IV patent infringement action

Par's ANDA filing certified that the asserted patent was invalid, unenforceable, or would not be infringed. That certification triggered Janssen's statutory right to sue under 21 U.S.C. § 355(j)(5)(B)(iii).

What patent did Janssen assert against Par?

Janssen asserted U.S. Patent No. 8,822,438, titled "Methods and compositions for treating cancer." The patent claimed methods using abiraterone acetate in prostate-cancer treatment.

The patent was important because the earlier abiraterone compound patent had expired, leaving method-of-use and formulation-related rights as potential barriers to generic entry. The '438 patent was listed in the FDA Orange Book for Zytiga and carried an expiration date in 2027, subject to applicable patent-term adjustments or extensions reflected in the FDA listing. [1]

The key commercial issue was whether a generic applicant could market abiraterone acetate for uses outside the patented indication or rely on a Section viii carve-out from the ANDA labeling.

What did the '438 patent cover?

The asserted patent covered treatment methods involving:

• Abiraterone acetate administration;
• Prostate-cancer treatment;
• Use in combination with other cancer therapies;
• Dosing and treatment regimens directed to androgen deprivation.

The patent was a method-of-use patent rather than a basic composition-of-matter patent. That distinction affected both infringement analysis and the ability of generic companies to pursue label-carveout strategies.

What were Par's Paragraph IV arguments?

Par's Paragraph IV position placed the '438 patent's validity and scope directly in dispute. The principal legal issues in the Zytiga litigation included:

1. Obviousness under 35 U.S.C. § 103;
2. Anticipation under 35 U.S.C. § 102;
3. Written description and enablement;
4. Infringement based on the proposed ANDA labeling;
5. The availability and effectiveness of a Section viii carve-out;
6. Whether the claimed dosing regimen provided a patentable technical contribution.

Par's filing created the statutory 30-month stay of FDA approval, although the stay could be shortened by a court judgment or resolved through settlement. The case therefore had two separate consequences: it delayed potential FDA approval and created settlement leverage over the generic launch date.

When did Janssen v. Par settle?

The Par action was resolved without a reported trial judgment on the validity of the '438 patent. The docket reflects termination of the dispute following settlement-related proceedings.

The settlement terms were not publicly disclosed in a form that establishes every commercial provision. As a result, the public record does not support treating Par's settlement as an admission that the '438 patent was valid or infringed.

A Hatch-Waxman settlement generally may address:

• The earliest permitted generic launch date;
• Whether Par could launch before patent expiry;
• Authorized-generic supply arrangements;
• Patent litigation releases;
• Restrictions on the generic label;
• Acceleration provisions tied to other generic challengers.

The case's termination eliminated the immediate litigation against Par but did not determine the enforceability of the patent against other ANDA filers.

What was the later court ruling on the Zytiga patent?

The most important later development came from related litigation against Teva Pharmaceuticals. In that litigation, the District of Delaware held the '438 patent claims invalid for obviousness. The Federal Circuit affirmed the invalidity determination in Janssen Biotech Inc. v. Teva Pharmaceuticals USA Inc. [2]

The Federal Circuit's decision involved the same core Zytiga patent and addressed whether a skilled person would have been motivated to use abiraterone acetate with prednisone for the claimed prostate-cancer treatment. The court concluded that the asserted claims were obvious based on the prior art and the expected therapeutic rationale.

That ruling materially weakened Janssen's position across related Zytiga ANDA cases. Although a judgment in separate litigation does not automatically resolve every procedural issue in a different defendant's case, a final appellate holding that the patent claims are invalid removes the patent as a viable basis for blocking generic approval or launch.

What is the Orange Book status of Zytiga?

Zytiga was approved by the FDA in 2011 for treatment of metastatic castration-resistant prostate cancer. The FDA Orange Book identified Janssen's patents and exclusivity information for the product. [1]

Regulatory issue	Status
FDA approval	Approved
NDA	202379
Product	Abiraterone acetate tablets
Brand	Zytiga
ANDA pathway	Applicable
Orange Book patent	U.S. Patent No. 8,822,438
Patent type	Method of use
Regulatory exclusivity	Separate from patent protection
Pediatric exclusivity	Must be evaluated separately from patent expiry

Orange Book listing does not establish patent validity. It identifies patents that the NDA holder represents as covering the approved drug or an approved use. Generic applicants may challenge listed patents through Paragraph IV certifications or omit a patented use through a Section viii statement.

When did Zytiga lose exclusivity?

Zytiga's commercial exclusivity has several components:

Regulatory exclusivity

FDA regulatory exclusivity is distinct from patent exclusivity. Zytiga received the regulatory exclusivity applicable to its approval pathway, but that exclusivity did not permanently prevent ANDA approval after the statutory period expired.

Composition-of-matter protection

The original abiraterone patent protection expired before the asserted method-of-use patent. That left the '438 patent as a principal barrier in the later ANDA litigation.

Method-of-use protection

The '438 patent was listed with an expiration date in 2027. Its practical blocking power was reduced after the Federal Circuit affirmed invalidity in the related Teva litigation.

Settlement-based entry

Generic entry could occur before the listed patent expiration if Janssen granted a license or agreed to an earlier launch date. Therefore, the effective generic-entry date for Par depended on the settlement rather than on the nominal Orange Book expiration date alone.

Did Par receive FDA approval for generic abiraterone?

The litigation record does not establish a final FDA approval date for Par's ANDA from the court docket alone. FDA approval and commercial launch are separate events. A settlement may permit an applicant to obtain approval while restricting the date on which it may market the product.

For market analysis, the relevant sequence is:

1. Par filed an ANDA with a Paragraph IV certification.
2. Janssen filed the Delaware patent action.
3. The FDA approval process was subject to the Hatch-Waxman stay.
4. Janssen and Par settled the litigation.
5. Any later approval or launch depended on FDA action and the settlement's permitted-entry provisions.
6. The subsequent invalidity ruling against the '438 patent reduced the patent-based risk for remaining applicants.

How strong was Janssen's Zytiga patent estate?

Janssen's Zytiga estate was commercially important but legally narrower than a composition-of-matter estate.

Strength factor	Assessment
Approved product	Strong commercial position
Original compound patent	Expired before the later method patent
Method-of-use patent	Subject to obviousness challenge
Orange Book listing	Supported a Paragraph IV lawsuit
Formulation protection	Limited public evidence of a durable blocking formulation patent in this action
Manufacturing protection	Not the central basis of the Par case
Litigation leverage	High before final invalidity ruling
Long-term exclusionary strength	Substantially reduced after Federal Circuit affirmance

The patent's main vulnerability was obviousness. The asserted treatment approach used known pharmacology surrounding androgen biosynthesis inhibition and prednisone-based prostate-cancer treatment. The Federal Circuit's decision confirmed that the patent could not reliably support long-term exclusion of generic abiraterone products.

What formulation patents protected Zytiga?

The Par case centered on a method-of-use patent, not a broad formulation patent. Zytiga's commercial protection therefore depended primarily on:

• The drug's regulatory approval;
• The patent listed in the Orange Book;
• Method-of-use rights;
• Settlement restrictions;
• Potential manufacturing and supply-chain controls.

A generic applicant could reduce infringement exposure by using a label that omitted patented indications or dosing instructions, where FDA labeling rules permitted the carve-out. That strategy would not eliminate all risk if the remaining label induced use of the patented method.

What patent litigation affected generic Zytiga entry?

Janssen filed related actions against multiple ANDA applicants. The litigation campaign sought to enforce the '438 patent against companies preparing generic abiraterone acetate products.

The most consequential reported ruling was the Teva case:

Proceeding	Result
District of Delaware litigation	'438 patent claims held invalid for obviousness
Federal Circuit review	Invalidity judgment affirmed
Effect on Par case	Reduced practical value of Janssen's asserted patent
Effect on generic applicants	Weakened patent-based launch injunction risk
Effect on Orange Book listing	Listing did not preserve an invalid patent's exclusionary force

The later appellate ruling was more important to the competitive landscape than the Par settlement because it addressed the patent's merits.

Were there Paragraph IV settlements involving other generic manufacturers?

Zytiga litigation involved settlements with generic applicants. Public settlement details varied by company and were not always fully disclosed.

Settlement analysis should distinguish between:

• A license date;
• An authorized-generic arrangement;
• A no-challenge provision;
• A supply agreement;
• A covenant not to sue;
• A permitted launch date;
• A contingency tied to patent invalidity or another applicant's launch.

A settlement does not by itself validate the patent. It reflects the parties' negotiated allocation of litigation and launch risk at the time of settlement.

What generic entry risks existed after the Par settlement?

The principal generic-entry risks were:

Patent invalidity risk

The later Federal Circuit ruling eliminated the central validity barrier associated with the '438 patent.

Labeling risk

A generic applicant still had to ensure that its proposed label did not create induced-infringement exposure for a patented use. A Section viii carve-out could reduce that risk but had to comply with FDA requirements.

Regulatory risk

FDA approval timing, deficiencies, manufacturing inspections, and product quality requirements could delay launch independently of patent litigation.

Commercial risk

Generic abiraterone would face price erosion, payer substitution, wholesaler contracting pressure, and competition from multiple ANDA applicants. The first entrant could obtain a materially stronger market position than later entrants, particularly if it qualified for 180-day exclusivity.

Manufacturing risk

Abiraterone acetate tablets require validated manufacturing, control of active pharmaceutical ingredient supply, and compliance with FDA current good manufacturing practice requirements. Those issues could delay entry even after patent barriers were removed.

How did Janssen v. Par compare with other oncology patent cases?

The case illustrates the difference between a branded product protected by a composition patent and one protected primarily by a method-of-use patent.

Issue	Zytiga and '438 patent	Composition-of-matter case
Patent scope	Treatment method	Active ingredient itself
Label carve-out	Potentially significant	Usually less effective
Obviousness exposure	High if treatment rationale was predictable	Generally lower after valid discovery
Effect of invalidity ruling	Broad reduction in blocking power	Depends on remaining patents
Settlement leverage	Strong before merits ruling	Usually stronger near compound expiry
Generic launch path	ANDA with possible Section viii strategy	ANDA often requires full product approval

Janssen's position was strongest while the '438 patent remained presumptively valid and the 30-month stay remained in place. It weakened materially after the related appellate invalidity ruling.

What is the current commercial significance of the case?

The Par case is no longer a meaningful standalone barrier to generic abiraterone entry. Its commercial significance is historical and strategic:

• It records Janssen's enforcement of the Zytiga method-of-use patent;
• It shows how a Paragraph IV filing can trigger a patent settlement;
• It demonstrates the limits of a method-of-use strategy after a compound patent expires;
• It provides context for later invalidity rulings;
• It helps assess the likely value of similar oncology patent estates.

For licensing and litigation analysis, the later Federal Circuit decision should receive greater weight than the Par settlement. A settlement may preserve near-term revenue, but an appellate invalidity ruling determines whether the patent can support durable exclusion against the broader generic field.

Key Takeaways

• Janssen Biotech sued Par Pharmaceutical in Delaware over an ANDA for generic abiraterone acetate tablets.
• The asserted patent was U.S. Patent No. 8,822,438, covering methods of treating prostate cancer with abiraterone acetate.
• The Par action ended through settlement rather than a reported merits judgment.
• The settlement terms and any specific Par launch date were not fully public.
• The '438 patent was later held invalid for obviousness in related litigation against Teva.
• The Federal Circuit's affirmance substantially reduced Janssen's ability to use the patent to block generic Zytiga entry.
• The case involved method-of-use protection, not a durable composition-of-matter barrier.
• Generic entry depended on the interaction of FDA approval, Section viii labeling, settlement rights, and the later appellate invalidity ruling.

FAQs

What was Janssen Biotech v. Par Pharmaceutical about?

It was a Hatch-Waxman patent infringement case concerning Par's ANDA for generic abiraterone acetate tablets, marketed by Janssen as Zytiga.

Which patent did Janssen assert against Par?

Janssen asserted U.S. Patent No. 8,822,438, a method-of-use patent covering prostate-cancer treatment with abiraterone acetate.

Did Par win the Zytiga patent case?

The Par action ended through settlement and did not produce a reported final merits judgment against Par. The related Teva litigation later resulted in invalidation of the '438 patent.

Can a generic company launch abiraterone after the '438 patent ruling?

The Federal Circuit's affirmance of invalidity removed the principal patent-based barrier associated with the '438 patent. FDA approval, labeling, manufacturing readiness, and any separate settlement restrictions still affected launch timing.

Was Zytiga protected by a formulation patent?

The Par case was based primarily on a method-of-use patent. The public record does not identify a durable formulation patent as the central asserted barrier in this action.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Court of Appeals for the Federal Circuit. (2023). Janssen Biotech, Inc. v. Teva Pharmaceuticals USA, Inc., 97 F.4th 915.

3. U.S. District Court for the District of Delaware. (2015). Janssen Biotech Inc. v. Par Pharmaceutical Inc., No. 1:15-cv-00679.

4. U.S. Food and Drug Administration. (2011). FDA approves Zytiga for late-stage prostate cancer. https://www.fda.gov

5. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,822,438: Methods and compositions for treating cancer.